These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 9310341)

  • 1. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
    Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
    Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones.
    Cory JG; Cory AH; Rappa G; Lorico A; Liu MC; Lin TS; Sartorelli AC
    Biochem Pharmacol; 1994 Jul; 48(2):335-44. PubMed ID: 8053929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
    Crenshaw TR; Cory JG
    Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory JG; Cory AH; Lorico A; Rappa G; Sartorelli AC
    Anticancer Res; 1997; 17(5A):3185-93. PubMed ID: 9413147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double knockout of the MRP gene leads to increased drug sensitivity in vitro.
    Lorico A; Rappa G; Flavell RA; Sartorelli AC
    Cancer Res; 1996 Dec; 56(23):5351-5. PubMed ID: 8968083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein-mediated multidrug resistance phenotype of L1210/VCR cells is associated with decreases of oligo- and/or polysaccharide contents.
    Fiala R; Sulová Z; El-Saggan AH; Uhrík B; Liptaj T; Dovinová I; Hanusovská E; Drobná Z; Barancík M; Breier A
    Biochim Biophys Acta; 2003 Nov; 1639(3):213-24. PubMed ID: 14636953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
    Kim WJ; Kakehi Y; Yoshida O
    Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
    Barrand MA; Bagrij T; Neo SY
    Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
    Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
    Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
    Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
    Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines.
    Modrak DE; Draper MP; Levy SB
    Biochem Pharmacol; 1997 Dec; 54(12):1297-306. PubMed ID: 9393672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional expression of yeast artificial chromosome-human multidrug resistance genes in mouse cells.
    Kusaba H; Kohno K; Asakuno K; Kuwano M; Okumura K; Green ED; Schlessinger D; Wada M
    Genome Res; 1995 Oct; 5(3):245-58. PubMed ID: 8593612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells.
    Wada H; Saikawa Y; Niida Y; Nishimura R; Noguchi T; Matsukawa H; Ichihara T; Koizumi S
    Exp Hematol; 1999 Jan; 27(1):99-109. PubMed ID: 9923448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
    Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
    Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance: molecular mechanisms and clinical relevance.
    Ling V
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
    Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
    Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
    Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
    Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
    Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
    Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.